GlassScriptPhysician profile
Molly Lutz
NPI 1821588476
$70,597.06
in general payments reported to CMS, 2019-2025
21 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,560 · 2022: $18K · 2023: $21K · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $6,879 · Travel and Lodging: $1,510 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,575.00 |
| Food and Beverage | $6,879.24 |
| Travel and Lodging | $1,509.54 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,721.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $909.80 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $622.25 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $612.97 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $563.43 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $471.18 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $450.41 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $435.62 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $350.73 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $320.19 | 2021-2025 | Caplyta |
| Corium, LLC | $274.22 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $264.49 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $200.77 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $152.29 | 2022-2025 | Fanapt, Hetlioz |
| Noven Therapeutics, LLC | $49.66 | 2023-2024 | Xelstrym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $46.32 | 2023-2025 | Loreev Xr, Gralise |
| Avanir Pharmaceuticals, INC. | $43.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $33.81 | 2021-2024 | |
| Bausch Health US, LLC | $31.47 | 2022-2023 | Wellbutrin, Aplenzin |
| Ironshore Pharmaceuticals INC. | $29.45 | 2022-2023 | Jornay Pm |
| Alfasigma USA, INC. | $13.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Lutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.